Supported by more than 15 clinical trials
Identified and commercialised in 1998, the Lab4 probiotics consortium contains four proprietary bacteria strains – Lactobacillus acidophilus CUL60, Lactobacillus acidophilus CUL21, Bifidobacterium animalis subsp. lactis CUL34 and Bifidobacterium bifidum CUL20.
The Lab4 probiotics blend is supported by more than 15 clinical trials and a number of in vitro and in vivo studies across a wide range of conditions at doses ranging from 12.5 billion CFUs to 50 billion CFUs per day. The conditions studied to date include C. difficile, using probiotics alongside antibiotics, irritable bowel syndrome (IBS), immunity, upper respiratory tract infection (URTI), mood and performance.